Medulloblastoma sub-typing

Medulloblastoma sub-typing

Medulloblastoma is the most frequently occurring malignant brain tumour in children, with an approximate incidence of 1.5 cases per million, rising to 6 per million in children aged 1 to 9 years. It also occurs in adults, although in this group it is around ten times less common.

Cases of the disease can be placed into one of four distinct subgroups on the basis of characteristic patterns of gene expression which can be determined by promoter methylation state analysis; WNT, SHH, Group 3 and Group 4.

Each group has distinct molecular, clinical and pathological features and classification is an important step in determining the most appropriate course of treatment and follow-up for individual patients.

The assay provided by NewGene was developed in co-operation with Professor Steve Clifford’s group at Newcastle University and Agena Biosciences, and is performed using the Agena Biosciences MassARRAY instrument.

Details of the assay have been published in Nature Scientific Reports - click to view the pdf file.

Read the CLI article here.

Contact us

NewGene Limited
Bioscience Building
International Centre for Life
Newcastle upon Tyne
NE1 4EP, UK

Tel: +44 (0)191 242 1923
Fax: +44 (0)191 241 8799
Email: info@newgene.org.uk

Click here for location map

Mon – Fri 08:30 to 17:00, closed Bank Holidays

An ISO 15189 accredited Medical Laboratory company

NewGene Limited | Company Number: 06735445

Technology Partners

Agilent Technologies

Agena Bioscience

Illumina

Sophia Genetics

Qiagen

Promega

Enquiry form